Jan Johansson

Artery Therapeutics, Inc.

$8,291,590

Attributed

$8,291,590

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $2.5M · FY2019–25

$2.5M$1.9M$1.3M$625K$0

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$8,291,590 · 3

By mechanism

R44$8,291,590 · 3

Top collaborators

No co-investigators on record.

Others in their field

Other Emerging Leaders on “Alzheimer&Apos”

Lance Allen Johnson · University Of Kentucky$7,508,882
Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
Jessica Brooke Langbaum · Banner Health$6,050,741
Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362

Research focus

Alzheimer&AposApolipoprotein E-4BrainSafetyBindingAlzheimerâS Disease BiomarkerFemalePhase 1 StudyClinical TrialsCholesterolDementiaDoseAgonistArteriesReportingBiological MarkersMalePharmaceutical PreparationsS DiseaseAmyloid Beta-ProteinDisease MarkerLipidsLipoproteinsGenetic Risk Factor

Grant awards (5)

Manufacturing of ABCA1 agonist small molecule peptide CS6253 to support chronic toxicology studies in Wistar rats and Cynomolgus monkeys$2,454,521

R44 · FY2025 · AG · contact PI

A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253$2,482,205

R44 · FY2023 · AG · contact PI

R44 · FY2021 · AG · contact PI

CS6253 development for the treatment of apoE4 driven dementia includingAlzheimer's disease$2,375,985

R44 · FY2020 · AG · contact PI

CS6253 development for the treatment of apoE4 driven dementia includingAlzheimer's disease$479,682

R44 · FY2019 · AG · contact PI